Company news
Eupraxia Pharmaceuticals, Inc. news in 2024
Eupraxia Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Eupraxia's DiffuSphere(TM) Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
November 20, 2024
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
November 14, 2024
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
November 13, 2024
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
November 12, 2024
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 7, 2024
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
October 31, 2024
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
October 28, 2024
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
October 15, 2024
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
October 10, 2024
Eupraxia Pharmaceuticals Strengthens Senior Management Team
October 2, 2024
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
September 11, 2024
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 7, 2024
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
August 2, 2024
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
July 8, 2024
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
July 3, 2024
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
June 5, 2024
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
May 23, 2024
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
May 22, 2024
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
May 21, 2024
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
May 14, 2024
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
May 2, 2024
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
April 11, 2024
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
April 8, 2024
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
April 5, 2024
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
April 3, 2024
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
April 1, 2024
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
February 5, 2024
Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR
February 1, 2024
Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee
January 30, 2024
Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf Prospectus
January 8, 2024